CNIPA.AI
Sign In

All tools

Patent applicant records

APPLICANTS

天科雅生物科技有限公司

Browse source applicant names and unchanged name fields from imported patent records.

These are name-based results, not verified legal entities. Identical names may refer to different people or organizations; aliases and historical names are not merged.

This name was extracted from a distinct applicant node in the source XML.

1 indexed patent records

Patent counts refer to distinct records held by this site, not an applicant’s complete portfolio. A joint name field is not a single company.

Verified corpus date coverage and last import time are not currently available. Publication dates on patent records are not import dates. Cached directory results may lag behind new imports.

Search the local original applicant field containing this full text. Results may include joint lists or longer names; this is not an exact identity search.

Search patents with this applicant condition
Open patent writing
№ CN122996084AInvention
Unknown

重新用于IL-9信号传导的工程化TGFβ受体及其在免疫细胞中的应用

提供了一种将在免疫细胞（例如，T细胞）中表达的工程化TGFβ受体系统，在TGFβ结合后，该系统重新用于转导免疫支持性白细胞介素9（IL‑9）信号，而不是由在免疫细胞中表达的内源性TGFβ受体所介导的通常的免疫抑制性TGFβ信号。该工程化TGFβ受体系统包括两条工程化嵌合TGFβ受体链，它们的细胞外部分分别编码TGFβR1和TGFβR2的细胞外结构域，而它们的细胞内部分分别编码IL9R和IL2γ的细胞内结构域。用这样的工程化TGFβ受体系统修饰的T细胞表现出强JAK‑STAT信号传导，并且在TGFβ刺激时，尤其是在反复抗原刺激下，表现出高存活率和增殖能力。此类工程化免疫细胞在治疗通常以具有富含TGFβ的免疫抑制环境为特征的实体瘤中，有望具有增强的持久性和改善的控制。

❖杭州厚无生物医药科技有限公司; 天科雅生物科技有限公司; 广东天科雅生物医药科技有限公司; 天科雅香港有限公司陈锐; 余见帅; 杨宏波; 苏震波Oct 27, 2026§ 5/80 ClaimsC07K 19/00 (2006.01), C12N 5/10 (2006.01), A61K 35/17 (2006.01) +1